Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Launches New Reagent Kits for the MiSeq® System

Published: Thursday, August 22, 2013
Last Updated: Thursday, August 22, 2013
Bookmark and Share
Latest milestone doubles sequencing output to 15Gb, enables applications including exome sequencing.

Illumina, Inc. has announced the availability of its newest reagent kits for the MiSeq, the industry's most accurate and easiest-to-use benchtop sequencer.

The improved chemistry doubles sequencing output to 15 gigabases (Gb) by increasing the number of sequencing reads (up to 25 million reads) and overall read length (up to 2x300 base pairs).

These innovations enable researchers to perform new applications including exome sequencing on the MiSeq.

In addition, increased sequencing reads will support transcriptome applications such as mRNA sequencing and will offer higher throughput capacity for gene expression profiling with Illumina's TruSeq Targeted RNA Expression assay.

The benefits of increased paired-end read lengths include improving the quality of genome assemblies and advancing applications that require longer read lengths, such as metagenomics and human leukocyte antigen (HLA) typing.

"The new MiSeq kits are another example of how we are focused on continually improving the performance and value of our sequencing platforms for our customers," said Christian Henry, Senior Vice President and General Manager of Illumina's Genomic Solutions business.

Henry continued, "The latest MiSeq system enhancements deliver the highest data quality and will open up new applications for researchers in markets as diverse as cancer, genetic disease, microbiology, agriculture and forensics."

Added Dr. Ellen Heitzer of the Institute for Human Genetics, Medical University of Graz in Austria, "As a beta customer, we have seen even more robust MiSeq performance with the new chemistry, including the ability to pool more samples for our circulating tumor assay. We've also seen excellent sequencing quality, with almost 90 percent of clusters passing the filter and 96 percent of reads with a quality score greater than 30. In addition, the longer read length will facilitate the identification of translocations and fusion genes for our target resequencing approaches."

The new MiSeq reagent kits are now shipping, including a 600-cycle kit and a 150-cycle kit. For more information visit, www.illumina.com/MiSeq.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Forms New Company
GRAIL to enable early cancer detection via blood-based screening.
Tuesday, January 12, 2016
Novogene and Illumina Enters into Agreement
Agreement to co-develop NGS diagnostic system for reproductive health and oncology applications.
Wednesday, December 16, 2015
Amoy Diagnostics and Illumina Enter Strategic Collaboration
Collaboration for next-generation sequencing cancer diagnostics in China.
Thursday, October 01, 2015
Illumina Joins WIN Consortium in Personalized Cancer Medicine
A global network of leading academic, industry, insurance and non-profit research organizations.
Thursday, September 24, 2015
MSK and Illumina Launch Comprehensive Circulating Tumor DNA Program
Collaboration aims to determine range of opportunities for non-invasive cancer diagnosis and monitoring.
Thursday, September 17, 2015
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
Collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.
Tuesday, August 25, 2015
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Tuesday, July 14, 2015
Illumina Announces Oncology CDx Partnership with AstraZeneca, Janssen and Sanofi
Illumina, forms collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing (NGS)-based oncology test system.
Thursday, August 21, 2014
Illumina Appoints Senior VP of Oncology
Company names Tina S. Nova as Senior Vice President and General Manager of oncology.
Tuesday, July 15, 2014
Amgen and Illumina Enter Agreement
Illumina to develop IVD kit on its FDA-cleared MiSeqDx™ NGS instrument for Amgen’s Vectibix (Panitumumab).
Monday, January 20, 2014
Illumina Technology Enables Findings of COGS
Custom iSelect® genotyping array designed in collaboration with consortia to advance understanding of cancer.
Tuesday, May 28, 2013
Caris Life Sciences Selects Illumina’s MiSeq® System
Collaboration enhances breadth and depth of therapeutic information to help oncologists better personalize cancer treatment.
Friday, November 09, 2012
Illumina Announces Scale-Up of Genome Analyzers at the Broad Institute
Broad Institute has purchased 30 additional Genome Analyzers, increasing its total installed base of Illumina systems to 89.
Friday, November 06, 2009
Illumina Advances Genetic Analysis of Cancer
Illumina is launching software tools that enable customers to use Infinium™ SNP genotyping data.
Friday, December 16, 2005
Scientific News
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Cancer Cells Coordinate to Form Roving Clusters
Rice University scientists identify ‘smoking gun’ in metastasis of hybrid cells.
Poliovirus Therapy Wins 'Breakthrough' Status
FDA decision will fast-track research on breakthrough Duke brain cancer therapy.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
New Treatment for Pancreatic Cancer
Researchers at Purdue University have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Triple-Negative Breast Cancer Target Is Found
Researchers at UC Berkeley discover a target that drives cancer metabolism in triple-negative breast cancer.
Cancer Can Arise from Histone Mutations
A mutation that affects the proteins that package DNA—without changing the DNA itself—can cause a rare form of cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!